ES2145730T1 - Un metodo para quimioprevencion de cancer de prostata. - Google Patents

Un metodo para quimioprevencion de cancer de prostata.

Info

Publication number
ES2145730T1
ES2145730T1 ES99924157T ES99924157T ES2145730T1 ES 2145730 T1 ES2145730 T1 ES 2145730T1 ES 99924157 T ES99924157 T ES 99924157T ES 99924157 T ES99924157 T ES 99924157T ES 2145730 T1 ES2145730 T1 ES 2145730T1
Authority
ES
Spain
Prior art keywords
prostate
chemioprevention
cancer
formula
different
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES99924157T
Other languages
English (en)
Other versions
ES2145730T3 (es
Inventor
Mitchell S Steiner
Sharon Raghow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tennessee Research Foundation
Original Assignee
University of Tennessee Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tennessee Research Foundation filed Critical University of Tennessee Research Foundation
Publication of ES2145730T1 publication Critical patent/ES2145730T1/es
Application granted granted Critical
Publication of ES2145730T3 publication Critical patent/ES2145730T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Empleo de un agente quimiopreventivo en la preparación de un preparado farmacéutico para uso en un método para prevenir carbinogenesis de prostata en un mamífero, comprendiendo dicho agente quimiopreventivo un compuesto de la fórmula: *formula* (1) en donde R1 y R2, que pueden ser iguales o diferentes, son H o OH; R3 es OCH2CH2NR4R5, en donde R4 y R5, que pueden ser iguales o diferentes, son H o un grupo de alquilo con l a alrededor de 4 átomos de carbono, o una sal farmacéuticamente aceptable, éster, N-óxido o sus mezclas.
ES99924157T 1998-05-07 1999-05-07 Medicamento para el tratamiento de la neoplasia intraepitelial de prostata. Expired - Lifetime ES2145730T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8460298P 1998-05-07 1998-05-07
US84602P 1998-05-07

Publications (2)

Publication Number Publication Date
ES2145730T1 true ES2145730T1 (es) 2000-07-16
ES2145730T3 ES2145730T3 (es) 2005-06-16

Family

ID=22186034

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99924157T Expired - Lifetime ES2145730T3 (es) 1998-05-07 1999-05-07 Medicamento para el tratamiento de la neoplasia intraepitelial de prostata.

Country Status (26)

Country Link
US (1) US6265448B1 (es)
EP (3) EP1475087A3 (es)
JP (2) JP4482229B2 (es)
AT (1) ATE283043T1 (es)
AU (1) AU761435B2 (es)
BG (1) BG65597B1 (es)
CA (1) CA2323809C (es)
CZ (1) CZ300960B6 (es)
DE (2) DE1003496T1 (es)
DK (1) DK1003496T3 (es)
EA (1) EA003466B1 (es)
ES (1) ES2145730T3 (es)
HR (1) HRP20000729A2 (es)
HU (1) HUP0102068A3 (es)
IL (3) IL138437A0 (es)
IS (2) IS2213B (es)
NO (1) NO20005625L (es)
NZ (1) NZ527522A (es)
PL (1) PL207462B1 (es)
PT (1) PT1003496E (es)
SI (1) SI1003496T1 (es)
SK (1) SK16642000A3 (es)
TR (1) TR200003269T2 (es)
UA (1) UA74532C2 (es)
WO (1) WO1999056739A1 (es)
YU (1) YU68600A (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040092602A1 (en) * 1998-05-07 2004-05-13 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US20030130316A1 (en) * 2000-03-20 2003-07-10 Steiner Mitchell S. Method for chemoprevention of prostate cancer
US20040176470A1 (en) * 1998-05-07 2004-09-09 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
IL138437A0 (en) * 1998-05-07 2001-10-31 Univ Tennessee Res Corp Method for chemoprevention of prostate cancer
US6413534B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
WO2001017480A2 (en) * 1999-09-09 2001-03-15 Androsolutions, Inc. Methods and compositions for preventing and treating urinary tract disorders
US6642274B1 (en) 1999-09-09 2003-11-04 Gary W. Neal Methods and compositions for preventing and treating prostate disorders
US20040096510A1 (en) * 2001-11-29 2004-05-20 Steiner Mitchell S. Prevention and treatment of androgen-deprivation induced osteoporosis
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20050080143A1 (en) * 2001-11-29 2005-04-14 Steiner Mitchell S. Treatment of androgen-deprivation induced osteoporosis
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
DK1460969T3 (da) 2001-11-29 2008-09-01 Gtx Inc Forebyggelse og behandling af ved androgen-berövelse fremkaldt osteoporose
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20040213841A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S Methods for treating hot flashes and gynecomastia
US7524866B2 (en) * 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
US7070816B2 (en) * 2003-12-05 2006-07-04 New Chapter, Inc. Methods for treating prostatic intraepithelial neoplasia with herbal compositions
US20050208159A1 (en) * 2004-03-16 2005-09-22 Kang Kyung S Phytoestrogenic composition comprising an extract of chinese licorice root, liquiritin or isoliquiritin
US20060019989A1 (en) * 2004-07-21 2006-01-26 Steiner Mitchell S Compositions comprising 5-alpha reductase inhibitors and SERMs and methods of use thereof
WO2006052922A2 (en) * 2004-11-08 2006-05-18 Eastman Chemical Company Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds
WO2006052921A2 (en) * 2004-11-08 2006-05-18 Eastman Chemical Company Cyclodextrin solubilizers for liquid and semi-solid formulations
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
USD969722S1 (en) 2021-09-28 2022-11-15 Wagner Delima Stabilizing wedge pad

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4329364A (en) 1974-09-11 1982-05-11 Schering Corporation Antiandrogenic agents and methods for the treatment of androgen dependent disease states
US4474813A (en) 1980-10-24 1984-10-02 Schering Corporation Pharmaceutical preparations comprising flutamide
FI77839C (fi) * 1982-05-27 1989-05-10 Farmos Oy Foerfarande foer framstaellning av nya terapeutiskt effektiva trifenylalkan- och alkenderivat.
GB2126576B (en) * 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
US5491173A (en) 1982-06-25 1996-02-13 Orion-Yhtyma Oy Tri-phenyl alkene derivatives and their preparation and use
US5595985A (en) 1989-03-10 1997-01-21 Endorecherche Inc. Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
US4990538A (en) 1989-08-23 1991-02-05 Harris Adrian L Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs
GB9126209D0 (en) * 1991-12-10 1992-02-12 Orion Yhtymae Oy Drug formulations for parenteral use
GB9207437D0 (en) 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
AU687767B2 (en) * 1992-12-01 1998-03-05 Oy Biotie Therapies Ltd Syndecan stimulation of cellular differentiation
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
ATE406909T1 (de) 1993-05-13 2008-09-15 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
AU693459B2 (en) 1993-08-09 1998-07-02 Edward Baral A method for sensitization of cancer cells for killer cell mediated lysis
US5650425A (en) 1994-04-04 1997-07-22 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists
US5629007A (en) 1995-03-21 1997-05-13 Eli Lilly And Company Method of preventing prostatic cancer development
US5635197A (en) 1995-03-21 1997-06-03 Eli Lilly And Company Treatment and prevention of prostatic cancer metastasis
ZA984650B (en) * 1997-06-19 1998-12-08 Orion Corp Intratumoral administration of triphenylethylenes for the treatment of cancer
IL138437A0 (en) * 1998-05-07 2001-10-31 Univ Tennessee Res Corp Method for chemoprevention of prostate cancer

Also Published As

Publication number Publication date
AU4072699A (en) 1999-11-23
IS2213B (is) 2007-03-15
DE69922131D1 (de) 2004-12-30
EA200000100A1 (ru) 2000-08-28
US6265448B1 (en) 2001-07-24
CZ300960B6 (cs) 2009-09-23
JP2008163048A (ja) 2008-07-17
EP1003496A1 (en) 2000-05-31
DK1003496T3 (da) 2005-04-04
DE1003496T1 (de) 2000-11-02
CA2323809C (en) 2007-09-18
BG105022A (bg) 2001-07-31
IL138437A (en) 2008-12-29
CA2323809A1 (en) 1999-11-11
AU761435B2 (en) 2003-06-05
EA003466B1 (ru) 2003-06-26
PL207462B1 (pl) 2010-12-31
IS5700A (is) 2000-11-01
EP1475087A3 (en) 2007-07-11
JP2002513755A (ja) 2002-05-14
NO20005625L (no) 2001-01-05
ATE283043T1 (de) 2004-12-15
IS8354A (is) 2006-03-15
UA74532C2 (en) 2006-01-16
IL138437A0 (en) 2001-10-31
BG65597B1 (bg) 2009-02-27
NO20005625D0 (no) 2000-11-07
JP4482229B2 (ja) 2010-06-16
NZ527522A (en) 2005-04-29
EP2277514A1 (en) 2011-01-26
SK16642000A3 (sk) 2002-08-06
DE69922131T2 (de) 2005-11-24
ES2145730T3 (es) 2005-06-16
YU68600A (sh) 2003-12-31
EP1003496B1 (en) 2004-11-24
EP1475087A2 (en) 2004-11-10
HUP0102068A2 (hu) 2002-05-29
HUP0102068A3 (en) 2002-11-28
HRP20000729A2 (en) 2001-06-30
PT1003496E (pt) 2005-04-29
CZ20004118A3 (cs) 2002-07-17
IL193231A0 (en) 2009-02-11
SI1003496T1 (en) 2005-10-31
PL344000A1 (en) 2001-09-10
TR200003269T2 (tr) 2001-02-21
WO1999056739A1 (en) 1999-11-11

Similar Documents

Publication Publication Date Title
ES2145730T1 (es) Un metodo para quimioprevencion de cancer de prostata.
AR011846A1 (es) Una composicion farmaceutica, y el procedimiento para prepararla
AU691476B2 (en) Injectable taxane derivative based compositions
MX9302214A (es) Derivados de taxol y proceso para su preparacion
ES2148223T3 (es) Taxol encapsulado en liposomas y metodo para su uso.
GEP20022822B (en) Process for Preparing Derivatives of the Taxoid Family
NO2004005I2 (no) Pimecrolimus
AR035482A1 (es) Uso de un compuesto de cianoquinolina para la manufactura de un medicamento para tratar o inhibir polipos colonicos
DK0749432T3 (da) 9-deoxotaxan-forbindelser
ES2114931T3 (es) Nuevos esteres esteroidales.
ES2134804T3 (es) Uso de un compuesto generador de oxido nitrico para prevenir daño neuronal.
EP0460062A4 (en) Method for the synthesis of huperzine a and analogs thereof and compounds useful therein
KR970707108A (ko) 항염증제로 유용한, 복소환부를 갖는 디-t-부틸페놀 화합물(DI-TERT-BUTYLPHENOL COMPOUNDS WITH HETEROCYCLIC MOIETY, USEFUL AS ANTI-INFLAMMATORY AGENTS)
BR9914787A (pt) Processo para a preparação de um composto
AR012124A1 (es) Un procedimiento para la preparacion de derivados de tiazolidinadiona, derivados de tiazolidinadiona, su uso y preparados farmaceuticos que contienen a dichos derivados.
MX9206127A (es) Compuestos de acetileno
AU579497B2 (en) Peptic ulcer treatment method
BR9407257A (pt) Composto do tipo bis-naftalimida composição farmacêutica processo para tratamento de um tumor em mamifero uso do composto do tipo bis-naftalimida e processo para a preparação compostos do tipo bis-naftalimida
EP1192939A3 (en) Methods for reduction of inflammation and erythema
KR950703941A (ko) 일산화질소 합성 억제제(nitrogen monoxide synthesis inhibitor)
ATE200223T1 (de) Sampangin-derivate zur verwendung als antimykotische und antimykobakterielle wirkstoffe
KR920017668A (ko) 암 전이 억제 또는 예방 방법 및 이를 위한 제제
EP0194164A3 (en) N-carboxyalcoyl-2-oxo-3-diaryl-5,6-triazines useful as therapeutic agents
DK1133596T3 (da) Hydrofoberingsmiddel til efterbehandling af tekstiler
ITMI921833A0 (it) Metodo di preparazione di composti di inclusione di nimesulide con ciclodestrine